MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ILMN stock logo

ILMN

Illumina, Inc.

$219.4
6.16
 (2.89%)
Exchange:  NASDAQ
Market Cap:  33.195B
Shares Outstanding:  2.82M
Delayed data
Calculate ILMN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Diagnostics & Research
   
CEO:  Jacob Thaysen
Full Time Employees:  8600
Address: 
5200 Illumina Way
San Diego
CA
92122
US
Website:  https://www.illumina.com
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company’s offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina’s portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/04/30 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue4,504,0004,372,0004,338,000
Gross Profit2,744,0002,861,0002,893,000
EBITDA-608,000-725,0001,457,000
Operating Income-1,069,000-833,000864,000
Net Income-1,161,000-1,223,000850,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets10,111,0006,303,0006,644,000
Total Liabilities4,366,0003,930,0003,561,000
Total Stockholders Equity5,745,0002,373,0002,723,000
Total Debt2,262,0002,622,0002,475,000
Cash and Cash Equivalents1,048,0001,127,0001,418,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow478,000837,0001,079,000
Capital Expenditure-195,000-128,000-148,000
Free Cash Flow282,000709,000931,000
Net Income-1,161,000-1,223,000850,000
Net Change in Cash-963,00079,000291,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)5,891,869.608Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)6,152,669.199Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)5,999,533.333Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-682,915.270Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-653,967.829Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-665,917.960Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)1,354,104.968Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,432,455.969Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)1,386,450.008Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,886,972.497Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,970,498.048Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,921,453.655Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)8.890Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)9.180Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)8.680Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)7Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
4.372B  ?P/S
 (TTM)
: 
7.39
?Net Income
 (TTM)
: 
-1223000000  ?P/E
 (TTM)
: 
40.55
?Enterprise Value
 (TTM)
: 
34.682B  ?EV/FCF
 (TTM)
: 
36.94
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
31.08%  ?ROIC
 (TTM)
: 
13.54%
?Net Debt
 (TTM)
: 
1.402B  ?Debt/Equity
 (TTM)
: 
0.89
?P/B
 (TTM)
: 
11.67  ?Current Ratio
 (TTM)
: 
1.8

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
41.01Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates ILMN intrinsic value between $65.61 – $261.62 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ILMN valuation

Is Illumina, Inc. (ILMN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Illumina, Inc. (ILMN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ILMN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ILMN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ILMN’s P/E ratio?

You can see ILMN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ILMN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ILMN a good long-term investment?

Whether ILMN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ILMN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2.89
MARKETSnap

Trading Metrics:

Open: 212.4   Previous Close: 213.24
Day Low: 208.63   Day High: 220.43
Year Low: 88   Year High: 220.43
Price Avg 50: 186.4   Price Avg 200: 146.47
Volume: 1.913M   Average Volume: 1.86M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

What Makes Illumina (ILMN) a New Strong Buy Stock
07-08-2026 13:01
What Makes Illumina (ILMN) a New Strong Buy Stock
Illumina, Inc. (ILMN) Hits Fresh High: Is There Still Room to Run?
03-08-2026 10:16
Illumina, Inc. (ILMN) Hits Fresh High: Is There Still Room to Run?
Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Say
30-07-2026 20:31
Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Say
Insights Into Illumina (ILMN) Q2: Wall Street Projections for Key Metrics
29-07-2026 10:16
Insights Into Illumina (ILMN) Q2: Wall Street Projections for Key Metrics
Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown
22-07-2026 06:00
Fishbone Advisors Survey: Institutional Investors See Healthcare's AI Story as Overblown
Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know
09-07-2026 13:01
Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read